Engene Holdings Common Etf Current Valuation
| ENGN Etf | USD 8.69 0.08 0.91% |
Valuation analysis of enGene Holdings Common helps investors to measure EnGene Holdings' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Fundamental drivers impacting EnGene Holdings' valuation include:
Price Book 1.9144 | Enterprise Value 208.1 M | Enterprise Value Ebitda (6.01) |
Undervalued
Today
Please note that EnGene Holdings' price fluctuation is somewhat reliable at this time. Calculation of the real value of enGene Holdings Common is based on 3 months time horizon. Increasing EnGene Holdings' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since EnGene Holdings is currently traded on the exchange, buyers and sellers on that exchange determine the market value of EnGene Etf. However, EnGene Holdings' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 8.69 | Real 11.82 | Target 35.5 | Hype 9.1 | Naive 10.24 |
The intrinsic value of EnGene Holdings' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence EnGene Holdings' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of enGene Holdings Common helps investors to forecast how EnGene etf's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of EnGene Holdings more accurately as focusing exclusively on EnGene Holdings' fundamentals will not take into account other important factors: enGene Holdings Common ETF Current Valuation Analysis
EnGene Holdings' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current EnGene Holdings Current Valuation | 208.13 M |
Most of EnGene Holdings' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, enGene Holdings Common is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, enGene Holdings Common has a Current Valuation of 208.13 M. This is much higher than that of the Biotechnology family and significantly higher than that of the Health Care category. The current valuation for all United States etfs is notably lower than that of the firm.
EnGene Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses EnGene Holdings' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the etfs which would be a good addition to a portfolio. Peer analysis of EnGene Holdings could also be used in its relative valuation, which is a method of valuing EnGene Holdings by comparing valuation metrics of similar companies.EnGene Holdings is currently under evaluation in current valuation as compared to similar ETFs.
Fund Asset Allocation for EnGene Holdings
The fund consists of 97.03% investments in fixed income securities, with the rest of funds allocated in various types of exotic instruments.Asset allocation divides EnGene Holdings' investment portfolio among different asset categories to balance risk and reward by investing in a diversified mix of instruments that align with the investor's goals, risk tolerance, and time horizon. Mutual funds, which pool money from multiple investors to buy a diversified portfolio of securities, use asset allocation strategies to manage the risk and return of their portfolios.
Mutual funds allocate their assets by investing in a diversified portfolio of securities, such as stocks, bonds, cryptocurrencies and cash. The specific mix of these securities is determined by the fund's investment objective and strategy. For example, a stock mutual fund may invest primarily in equities, while a bond mutual fund may invest mainly in fixed-income securities. The fund's manager, responsible for making investment decisions, will buy and sell securities in the fund's portfolio as market conditions and the fund's objectives change.
EnGene Fundamentals
| Return On Equity | -1.23 | ||||
| Return On Asset | -0.22 | ||||
| Current Valuation | 208.13 M | ||||
| Shares Outstanding | 50.98 M | ||||
| Shares Owned By Insiders | 13.61 % | ||||
| Shares Owned By Institutions | 83.23 % | ||||
| Number Of Shares Shorted | 769.44 K | ||||
| Price To Book | 1.91 X | ||||
| EBITDA | (94.77 M) | ||||
| Net Income | (99.92 M) | ||||
| Total Debt | 9.78 M | ||||
| Book Value Per Share | 5.21 X | ||||
| Cash Flow From Operations | (24.74 M) | ||||
| Short Ratio | 5.74 X | ||||
| Earnings Per Share | (2.79) X | ||||
| Target Price | 28.13 | ||||
| Number Of Employees | 31 | ||||
| Beta | -0.76 | ||||
| Market Capitalization | 440.95 M | ||||
| Total Asset | 86.96 M | ||||
| Retained Earnings | (199.59 M) | ||||
| Working Capital | 80.18 M | ||||
| Year To Date Return | (0.98) % | ||||
| One Year Return | 4.07 % | ||||
| Three Year Return | 3.14 % | ||||
| Net Asset | 86.96 M | ||||
| Bond Positions Weight | 97.03 % |
About EnGene Holdings Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze enGene Holdings Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of EnGene Holdings using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of enGene Holdings Common based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with EnGene Holdings
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if EnGene Holdings position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in EnGene Holdings will appreciate offsetting losses from the drop in the long position's value.Moving against EnGene Etf
| 0.67 | ME | 23Andme Holding | PairCorr |
| 0.58 | DTIL | Precision BioSciences | PairCorr |
| 0.5 | VALN | Valneva SE ADR | PairCorr |
| 0.43 | A | Agilent Technologies | PairCorr |
| 0.41 | DRMA | Dermata Therapeutics | PairCorr |
The ability to find closely correlated positions to EnGene Holdings could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace EnGene Holdings when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back EnGene Holdings - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling enGene Holdings Common to buy it.
The correlation of EnGene Holdings is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as EnGene Holdings moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if enGene Holdings Common moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for EnGene Holdings can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in EnGene Etf
EnGene Holdings financial ratios help investors to determine whether EnGene Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in EnGene with respect to the benefits of owning EnGene Holdings security.